Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Temporal changes in the clinical approach to diagnosing prostate cancer.

Hilton WM, Padalecki SS, Ankerst DP, Leach RJ, Thompson IM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):162-8. doi: 10.1093/jncimonographs/lgs038.


An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.


Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.


Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD.

BJU Int. 2013 May;111(6):934-40. doi: 10.1111/j.1464-410X.2012.11768.x. Epub 2013 Jan 25. Retraction in: BJU Int. 2014 Mar;113(3):509.


[Clinical value of prostate specific antigen screening in early detection of prostate cancer].

Hua LX, Qiao D, Song NH, Feng NH, Yang J, Zhang JX, Chen JG, Zhang W, Sui YG, Wu HF.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):705-9. Chinese.


Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.

Punnen S, Nam RK.

Surg Oncol. 2009 Sep;18(3):192-9. doi: 10.1016/j.suronc.2009.02.006. Epub 2009 Mar 12. Review.


Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.


An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM.

J Natl Cancer Inst. 2011 Mar 16;103(6):462-9. doi: 10.1093/jnci/djr028. Epub 2011 Feb 24.


Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr, Thompson IM.

Cancer Prev Res (Phila). 2008 Aug;1(3):167-73. doi: 10.1158/1940-6207.CAPR-08-0078. Epub 2008 May 18.


Prostate specific antigen. Current clinical application and future prospects.

Duskova K, Vesely S.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):18-26. doi: 10.5507/bp.2014.046. Epub 2014 Oct 2. Review.


Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.


Prostatic specific antigen for prostate cancer detection.

Nogueira L, Corradi R, Eastham JA.

Int Braz J Urol. 2009 Sep-Oct;35(5):521-9; discussion 530-2. Review.


What is the risk posed by prostate cancer?

Albertsen PC.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):169-74. doi: 10.1093/jncimonographs/lgs028.


Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.


Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.

Cancer. 2010 Jun 1;116(11):2612-20. doi: 10.1002/cncr.25010.


Improving multivariable prostate cancer risk assessment using the Prostate Health Index.

Foley RW, Gorman L, Sharifi N, Murphy K, Moore H, Tuzova AV, Perry AS, Murphy TB, Lundon DJ, Watson RW.

BJU Int. 2016 Mar;117(3):409-17. doi: 10.1111/bju.13143. Epub 2015 May 24.


Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ.

Urology. 2002 Sep;60(3):469-73; discussion 473-4.


Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.

Lavallée LT, Binette A, Witiuk K, Cnossen S, Mallick R, Fergusson DA, Momoli F, Morash C, Cagiannos I, Breau RH.

Mayo Clin Proc. 2016 Jan;91(1):17-22. doi: 10.1016/j.mayocp.2015.07.030. Epub 2015 Dec 10.


[Current results on PSA-based prostate cancer detection].

Graefen M, Schlomm T, Steuber T, Sauter G.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Mar;57(3):312-7. doi: 10.1007/s00103-013-1905-0. German.


[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].

van der Kwast TH, Hoedemaeker RF, Schröder FH.

Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):972-6. Review. Dutch.


Supplemental Content

Support Center